NEW STABILITY INDICATING HIGH PERFORMANCE LIQUID CHROMATOGRAPHYMETHOD FOR THE DETERMINATION OF NIRMATRELVIR AND RITONAVIR INBULK AND TABLET DOSAGE FORM

Abstract

Nirmatrelvir and Ritonavir are prescribed to treat COVID-19. An cheap HPLC approach was developed and is utilized for validation. KH2PO4 and MeCN are combined in an Agilent C18 150x4.6mm, 5m column at a flow rate of 1 ml/min at a temperature of 30 oC using a 60:40 v/v ratio. Its length was 215.0 nm. Nirmatrelvir had a holding time of 2.243 hours, whereas Ritonavir took 2.815 hours. It was discovered that the %RSD was 0.5% and 0.5%. The Nirmatrelvir regression equation was: y = 58409x + 2794. It was also discovered that ritonavir was y = 59191x + 774.23. Additionally, the LOD and LOQ values were discovered, and all tests passed and met ICH criteria